bitBiome Accelerates Global Expansion with Strategic Leadership Hires
Tokyo, Japan, Palo Alto, CA – April 28, 2025– bitBiome, a pioneering force in the field of discovery, design and engineering of novel enzymes, proteins, and ingredients, using its proprietary microbial genome database, has announced a significant advancement in its global expansion strategy. The company has strategically appointed four distinguished experts in the field: Dipnath Baidyaroy, Aaron Hammons, Richard Fox, and Yuko Amizaki. These appointments highlight bitBiome’s unwavering dedication to accelerating the discovery and development of bio-based solutions on a global scale, positioning the company for continued growth and innovation in the burgeoning biomanufacturing sector.
Dr. Dipnath Baidyaroy joins bitBiome as Chief Business Officer, bringing more than two decades of experience in biotechnology and open innovation. Known for his track record in forging high-impact collaborations across academia and industry, Dipnath will lead bitBiome’s global partnering strategy, with a focus on expanding access to its proprietary single-cell genomics platform and database for the development of natural and custom enzymes, proteins, strains and ingredients. “bitBiome presents a unique opportunity for biotechnology in general as this is the only instance where the technology is forward-integrated into proprietary and diverse genome sequences whilst being back-integrated into bio-manufacturing,” said Dr. Baidyaroy.
Aaron Hammons joins bitBiome as the Global Head of Business Development with a focus on Life Science and Pharmaceuticals. Aaron has over two decades of experience in the pharmaceutical, biotech, and life science industries. He previously led the Global Life Sciences and Diagnostic division at Codexis, developing and commercializing improved enzymes, workflows, and platforms for reading, writing, and editing nucleic acids. “The development of tools and techniques for the life sciences will drive not only research forward, but healthcare as well. Vaccine development is critically dependent on these bio-based solutions, and I was impressed by the breadth of the enzymes present in the database that has clinical relevance,” said Mr. Hammons.
Dr. Richard Fox, a pioneer in protein engineering and machine learning for biodesign, joins the company as Head of Innovation. Dr. Fox is widely recognized for his contributions to the development of AI-driven enzyme engineering and data science tools and strategies for the rapid forward engineering of biological systems, encompassing proteins, pathways, and genomes. With over 25 years of leadership experience from roles at Inscripta and DuPont, Richard will advise on technological strategy, driving innovation at the intersection of AI and enzyme discovery. “I have been extremely impressed with bitBiome’s core technology and resulting database, encompassing sequences from largely untapped resources to date. bitBiome has at its disposal a massively valuable resource and our intent is to make that resource available to the industry for innovation in a wide range of field to include life science, agriculture, and pharmaceuticals,” said Dr. Fox, “this type of data is critical for our continued development of relevant machine learning models for biology. Our current models are only constrained by the data they can be trained on, and this database represents an entirely novel and diverse dataset for more advanced models.”
Yuko Amizaki assumes the role of Director of Business Development, overseeing bitBiome’s growing international footprint. Yuko has over 15 years of business development experience in the synthetic biology industry at companies including Zymergen, Intrexon and REG. Most recently, she was the Business Development Director at Bota Biosciences. “bitBiome has at its core, a widely relevant, and industry agnostic, platform that has the potential to make real-world contributions in the field of food and agriculture, life sciences, pharmaceutical sciences, and ingredient manufacture,” said Ms. Amizaki.
“Our mission has always been to unlock the full power of microbial genomes, as we know only about 0.001% of microbial genomes have been discovered to date,” said Yuji Suzuki, CEO of bitBiome. “With these new leaders on board, we are accelerating our global strategy—bringing together world-class science, technology, and operational excellence to solve the world’s toughest industrial and environmental challenges.”
bitBiome’s expansion marks a pivotal moment in its growth as it continues to harness its world-first single-cell genomics platform to unlock enzymes and proteins from nature that were previously inaccessible. These appointments will enable deeper integration with global markets, customers, and collaborators.
For more information, visit https://www.bitbiome.bio.
Email: info@bitbiome.bio